153 related articles for article (PubMed ID: 18348286)
1. High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling.
Bastien R; Lewis TB; Hawkes JE; Quackenbush JF; Robbins TC; Palazzo J; Perou CM; Bernard PS
Hum Mutat; 2008 May; 29(5):757-64. PubMed ID: 18348286
[TBL] [Abstract][Full Text] [Related]
2. High resolution melting for mutation scanning of TP53 exons 5-8.
Krypuy M; Ahmed AA; Etemadmoghadam D; Hyland SJ; ; DeFazio A; Fox SB; Brenton JD; Bowtell DD; Dobrovic A
BMC Cancer; 2007 Aug; 7():168. PubMed ID: 17764544
[TBL] [Abstract][Full Text] [Related]
3. Mutation scanning of exon 20 of the BRCA1 gene by high-resolution melting curve analysis.
Vorkas PA; Christopoulos K; Kroupis C; Lianidou ES
Clin Biochem; 2010 Jan; 43(1-2):178-85. PubMed ID: 19747471
[TBL] [Abstract][Full Text] [Related]
4. Oligonucleotide probe array for p53 gene alteration analysis in DNA from formalin-fixed paraffin-embedded breast cancer tissues.
Lumachi F; Marino F; Varotto S; Basso U
Ann N Y Acad Sci; 2009 Sep; 1175():89-92. PubMed ID: 19796081
[TBL] [Abstract][Full Text] [Related]
5. Quick-multiplex-consensus (QMC)-PCR followed by high-resolution melting: a simple and robust method for mutation detection in formalin-fixed paraffin-embedded tissue.
Fadhil W; Ibrahem S; Seth R; Ilyas M
J Clin Pathol; 2010 Feb; 63(2):134-40. PubMed ID: 20154035
[TBL] [Abstract][Full Text] [Related]
6. High sensitivity of detection of TP53 somatic mutations by fluorescence-assisted mismatch analysis.
Tessitore A; Di Rocco ZC; Cannita K; Ricevuto E; Toniato E; Tosi M; Ficorella C; Frati L; Gulino A; Marchetti P; Martinotti S
Genes Chromosomes Cancer; 2002 Sep; 35(1):86-91. PubMed ID: 12203794
[TBL] [Abstract][Full Text] [Related]
7. Application of multiplex PCR with histopathologic features for detection of familial breast cancer in formalin-fixed, paraffin-embedded histologic specimens.
Rassi H; Houshmand M; Hashemi M; Majidzadeh K; Akbari MH; Panahi MS
Tsitol Genet; 2008; 42(2):55-62. PubMed ID: 18630122
[TBL] [Abstract][Full Text] [Related]
8. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
[TBL] [Abstract][Full Text] [Related]
9. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
10. TP53 gene in blood plasma DNA of tumor patients.
Schlechte HH; Stelzer C; Weickmann S; Fleischhacker M; Schulze G
Ann N Y Acad Sci; 2004 Jun; 1022():61-9. PubMed ID: 15251941
[TBL] [Abstract][Full Text] [Related]
11. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
12. TP53 and breast cancer.
Børresen-Dale AL
Hum Mutat; 2003 Mar; 21(3):292-300. PubMed ID: 12619115
[TBL] [Abstract][Full Text] [Related]
13. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
[TBL] [Abstract][Full Text] [Related]
14. [Mutation scanning of short amplicons: optimization of DNA melting conditions].
Botezatu IV; Zhordania KI; Karseladze AI; Stroganova AM; Kondratova BN; Shelepov VP; Telkov MV; Likhtenshtein AV
Mol Biol (Mosk); 2012; 46(3):461-8. PubMed ID: 22888635
[TBL] [Abstract][Full Text] [Related]
15. Detection of clinically relevant point mutations by a novel piezoelectric biosensor.
Dell'Atti D; Tombelli S; Minunni M; Mascini M
Biosens Bioelectron; 2006 Apr; 21(10):1876-9. PubMed ID: 16388945
[TBL] [Abstract][Full Text] [Related]
16. Loss of TP53-DNA interaction induced by p.C135R in lung cancer.
Aranda M; Gonzalez-Nilo F; Riadi G; Díaz V; Perez J; Martel G; Hainaut P; Mimbacas A
Oncol Rep; 2007 Nov; 18(5):1213-7. PubMed ID: 17914575
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene.
Tõnisson N; Zernant J; Kurg A; Pavel H; Slavin G; Roomere H; Meiel A; Hainaut P; Metspalu A
Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5503-8. PubMed ID: 11960007
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.
Hosny G; Farahat N; Hainaut P
Cancer Lett; 2009 Mar; 275(2):234-9. PubMed ID: 19046801
[TBL] [Abstract][Full Text] [Related]
19. Frequent mutations in the mitochondrial control region DNA in breast tissue.
Rosson D; Keshgegian AA
Cancer Lett; 2004 Nov; 215(1):89-94. PubMed ID: 15374637
[TBL] [Abstract][Full Text] [Related]
20. Mutation scanning of the p53 tumor suppressor gene in renal and liver transplant patients in Hungary.
Sarvary E; Nagy P; Benjamin A; Szoke M; Remport A; Jansen J; Nemes B; Kobori L; Fehervari I; Sulyok B; Perner F; Varga M; Fazakas J; Lakatos M; Szabo M; Toth A; Járay J
Transplant Proc; 2005 Mar; 37(2):969-72. PubMed ID: 15848594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
